Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 4:16:27534030241312540.
doi: 10.1177/27534030241312540. eCollection 2025 Jan-Dec.

Effectiveness of Dupilumab Treatment in Patients With Type 2 Inflammation: A Real-Life Integrated Experience

Sara Torretta  1   2 , Gioia Piatti  3 , Chiara Catalano  2 , Silvia Ferrucci  4 , Mirta Cavallini  4 , Federica Rivolta  2   2 , Chiara Bellocchi  2   2 , Alice D'Adda  4 , Ludovica Battilocchi  1 , Simona Tavecchio  4 , Lorenzo Pignataro  1   2
Affiliations

Effectiveness of Dupilumab Treatment in Patients With Type 2 Inflammation: A Real-Life Integrated Experience

Sara Torretta et al. Ther Adv Allergy Rhinol. .

Abstract

Background: Type 2 inflammation plays a pivotal role in various allergic and inflammatory diseases, including chronic rhinosinusitis, asthma, atopic dermatitis, and eosinophilic esophagitis. Dupilumab is one of the emerging therapeutic targets that modulate the key mediators and cellular players involved in type 2 inflammation, aiming to improve the immune response and the quality of life of the patient.

Objective: Here, we describe the experience made on 792 patients enrolled by several specialists of a multidisciplinary team working on inflammatory type 2 diseases.

Design: Retrospective study.

Methods: Patients were treated with dupilumab according to the prescribed indications and were evaluated by several exams, tests, and questionnaires at baseline (T0) and after 12 (T1), 18 (T2), and 24 (T3) months.

Results: Overall, dupilumab exerts beneficial effects as demonstrated both by patients-reported outcomes and by objective assessments. Compared to baseline, all examined efficacy indicators showed an improvement after 12 months, with positive effects sustained through the 2 years of observation. Our results align with several previous trials.

Conclusion: Understanding the interconnection between different type 2 inflammatory diseases provides insight into potential avenues for precision medicine approaches and targeted therapies.

Keywords: ENT; allergology; asthma; atopic dermatitis; chronic rhinosinusitis; dermatology; dupilumab; eosinophilic esophagitis; immunology; pneumology; type 2 inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
The diagram shows how the “type-2 disease center” works and collaborates in a multidisciplinary way.
See this image and copyright information in PMC

References

    1. Gandhi NA, Bennett BL, Graham NM, Pirozzi G. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016; 15: 35–50. - PubMed
    1. Humeniuk P, Dubiela P, Hoffmann-Sommergruber K. Dendritic cells and their role in allergy: uptake, proteolytic processing and presentation of allergens. Int J Mol Sci 2017; 18: E1491. - PMC - PubMed
    1. Wise SK, Laury AM, Katz EH, et al. Interleukin-4 and interleukin-13 compromise the sinonasal epithelial barrier and perturb intercellular junction protein expression. Int Forum Allergy Rhinol 2014; 4: 361–370. - PMC - PubMed
    1. Fahy JV. Type 2 inflammation in asthma - present in most, absent in many. Nat Rev Immunol 2015; 15: 57–65. - PMC - PubMed
    1. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Br Med J. 2007; 335: 806–808. - PMC - PubMed